Author

A. Landry

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Z. Zador· 3 shared M. Balas· 2 shared M. Cusimano· 2 shared A. Saha· 1 shared J. C. Marshall· 1 shared M. D. Cusimano· 1 shared

Activity by Year

2018-2019 · peak 2/yr

Co-Author Collaboration Network

6 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Z. Zador

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Data driven analysis reveals shared transcriptome response and immune cell composition across aetiologies of critical illness.

Z. Zador, A. Landry, M. Balas, J. C. Marshall, M. D. Cusimano

The paper identifies shared immune cell composition and transcriptome responses across sepsis and trauma in critical illness, revealing subgroups associated with clinical outcomes.

bioRxiv · Jan 21, 2019 · PreprintImmunology

Skull base meningiomas have a distinct immune landscape.

Z. Zador, A. Landry, M. Balas, M. Cusimano

The paper analyzes bulk transcriptomics data from meningiomas to show that skull base meningiomas have a distinct immune landscape compared to convexity meningiomas.

bioRxiv · Jan 20, 2019 · PreprintCancer Biology

Homogenous subgroups of atypical meningiomas defined using oncogenic signatures: basis for a new grading system?

Z. Zador, A. Landry, A. Saha, M. Cusimano

The paper identifies two subgroups of atypical meningiomas using oncogenic signatures, reclassifying 72% of cases as either benign grade 1-like or malignant grade 3-like based on recurrence rates and biological processes.

bioRxiv · Dec 14, 2018 · PreprintCancer Biology